Abstract: A cell culture comprising a mammalian cell line which is modified to express a heterodimer consisting of a progranulin polypeptide and a prosaposin polypeptide.

Abstract: Embodiments include methods performed by a target RAN controller for handling relocation of a UE connection from a source RAN controller during an ongoing wireless communication. Such methods include, when a distance between the UE and a border between source and target RAN controllers is below a threshold value, receiving from the source RAN controller an order to establish radio link(s) to be controlled by the target RAN controller for the ongoing wireless communication and establishing radio link(s) for the ongoing wireless communication accordingly. Such methods include, based on existence of certain conditions, receiving from the source RAN controller a request to initiate a procedure for relocating the UE connection from source to target RAN controller. Such methods include creating an RRC configuration to be used by the UE after the relocation to the target RAN controller and sending the created RRC configuration to the source RAN controller.

Abstract: A method performed by a source Radio Network Controller (RNC) for handling a relocation of a User Equipment (UE) connection from the source RNC to a target RNC to serve the UE in an ongoing wireless communication is provided. An interface between the source RNC and the target RNC is available. When all radio links in the ongoing wireless communication are controlled by the target RNC and a triggering condition is fulfilled for relocation of the UE connection from the source RNC to the target RNC, the source RNC decides (202) to discontinue to use said interface. Then a core network is used for sending (204) to the target RNC, a triggering of the relocation procedure for relocating the source RNC to the target RNC to serve the UE. A Radio Resource Control (RRC) configuration defined by the target RNC to be used after the relocation to the target RNC is then obtained (205) via the core network.

Abstract: The present invention relates to a subtype selective partial agonist of ?6 containing nicotinic acetylcholine receptors. Due to its uniquely selective and functional profile, 9-methyl-3-pyridin-3-yl-3,9-diaza-bicyclo[3.3.1]nonane may be useful in the treatment, prevention and/or alleviation of a disease, disorder and/or condition which is responsive to activation of a nicotinic acetylcholine receptor (nAChR) in a subject, wherein the nAChR comprises at least one cholinergic receptor nicotinic alpha 6 subunit (nAChR?6). Preferably, said disease, disorder and/or condition is a Parkinsonian disorder or pain.

Abstract: A method performed by a source Radio Network Controller (RNC) for handling a relocation of a User Equipment (UE) connection from the source RNC to a target RNC to serve the UE in an ongoing wireless communication is provided. An interface between the source radio link to be controlled by target RNC for the ongoing RNC and the target RNC is available. When all radio links in the ongoing wireless communication are controlled by the target RNC and a triggering condition is fulfilled for relocation of the UE connection from the source RNC to the target RNC, the source RNC decides (202) to discontinue to use said interface. Then a core network is used for sending (204) to the target RNC, a triggering of the relocation procedure for relocating the source RNC to the target RNC to serve the UE. A Radio Resource Control (RRC) configuration defined by the target RNC to be used after the relocation to the target RNC is then obtained (205) via the core network.

Abstract: The present invention relates to generation of cell lines expressing recombinant proteins for use in naked and encapsulated cell biodelivery of secreted therapeutic molecules. In one embodiment the cell line is human. In another aspect of the invention the transposon system is used for generating a cell line for secretion of a biologically active polypeptide.

Abstract: The present invention relates to generation of cell lines expressing recombinant proteins for use in naked and encapsulated cell biodelivery of secreted therapeutic molecules. In one embodiment the cell line is human. In another aspect of the invention the transposon system is used for generating a cell line for secretion of a biologically active polypeptide.

Abstract: The invention comprises an implantable cell device that includes a membrane defining and enclosing a chamber; a distance body within the chamber for reducing the diffusion distance for a biological active factor to or across the membrane; and a support scaffold within the chamber for increasing the cell support surface area per unit volume of the chamber for distributing cells.

Abstract: The present invention relates to a subtype selective partial agonist of ?6 containing nicotinic acetylcholine receptors. Due to its uniquely selective and functional profile, 9-methyl-3-pyridin-3-yl-3,9-diaza-bicyclo[3.3.1]nonane may be useful in the treatment, prevention and/or alleviation of a disease, disorder and/or condition which is responsive to activation of a nicotinic acetylcholine receptor (nAChR) in a subject, wherein the nAChR comprises at least one cholinergic receptor nicotinic alpha 6 subunit (nAChRa6). Preferably, said disease, disorder and/or condition is a Parkinsonian disorder or pain.

Abstract: The present invention relates to the field of therapeutic use of proteins, genes and cells, in particular to the therapy based on the biological function of a secreted therapeutic protein, METRNL, in particular for the treatment of disorders of the nervous system. METRNL is a Nerve Survival and Growth factor with neuroprotective and/or neurogenesis effects.

Abstract: The present invention relates to generation of cell lines expressing recombinant proteins for use in naked and encapsulated cell biodelivery of secreted therapeutic molecules. In one embodiment the cell line is human. In another aspect of the invention the transposon system is used for generating a cell line for secretion of a biologically active polypeptide.

Abstract: The present invention relates to handover in a communications system, and more especially it relates cell change using Iu-interface dependent neighbor-cell lists, particularly in a Universal Mobile Telecommunications System, UMTS or WCDMA system.

Abstract: The present invention relates to generation of cell lines expressing recombinant proteins for use in naked and encapsulated cell biodelivery of secreted therapeutic molecules. In one embodiment the cell line is human. In another aspect of the invention the transposon system is used for generating a cell line for secretion of a biologically active polypeptide.

Abstract: The present invention relates to use of Cometin in a method of treatment of allodynia, hyperalgesia, spontaneous pain and/or phantom pain. In a preferred embodiment the disorder to be treated is thermal allodynia and thermal hyperalgesia. The Cometin polypeptide may be delivered as a polypeptide or by administration of an expression vector for expression of Cometin, a cell line transformed or transduced with said vector and a capsule comprising said cells.

Abstract: The present invention relates to the field of therapeutic use of proteins, genes and cells, in particular to the therapy based on the biological function of a secreted therapeutic protein, METRNL, in particular for the treatment of disorders of the nervous system. METRNL is a Nerve Survival and Growth factor with neuroprotective and/or neurogenesis effects.

Abstract: The invention features an implantable cell device that includes a membrane defining and enclosing a chamber; a distance body within the chamber for reducing the diffusion distance for a biological active factor to or across the membrane; and a support scaffold within the chamber for increasing the cell support surface area per unit volume of the chamber for distributing cells.

Abstract: The present invention relates to the field of therapeutic use of proteins, genes and cells, in particular to the therapy based on the biological function of a secreted therapeutic protein, METRNL, in particular for the treatment of disorders of the nervous system. METRNL is a Nerve Survival and Growth factor with neuroprotective and/or neurogenesis effects.

Abstract: The invention features an implantable cell device. The device includes a membrane defining and enclosing a chamber; a distance body, within the chamber, for reducing the diffusion distance for a biological active factor to or across the membrane; and a support scaffold, within the chamber, for increasing the cell support surface area per unit volume of the chamber for distributing cells.

Abstract: The present invention relates to use of Cometin in a method of treatment of allodynia, hyperalgesia, spontaneous pain and/or phantom pain. In a preferred embodiment the disorder to be treated is thermal allodynia and thermal hyperalgesia. The Cometin polypeptide may be delivered as a polypeptide or by administration of an expression vector for expression of Cometin, a cell line transformed or transduced with said vector and a capsule comprising said cells.

Abstract: The present invention relates to use of Cometin in a method of treatment of allodynia, hyperalgesia, spontaneous pain and/or phantom pain. In a preferred embodiment the disorder to be treated is thermal allodynia and thermal hyperalgesia. The Cometin polypeptide may be delivered as a polypeptide or by administration of an expression vector for expression of Cometin, a cell line transformed or transduced with said vector and a capsule comprising said cells.